+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

How patients' preferences for risk information influence treatment choice in a case of high risk and high therapeutic uncertainty: asymptomatic localized prostate cancer



How patients' preferences for risk information influence treatment choice in a case of high risk and high therapeutic uncertainty: asymptomatic localized prostate cancer



Medical Decision Making 19(4): 394-398



To assess how patients' preferences for non-numerical risk information are related to their tendency to choose early surgical treatment for asymptomatic gland-confined prostate cancer (a choice with high risk and high therapeutic uncertainty), the authors conducted a cross-sectional study of 228 patients receiving continuing care in a general medicine clinic. After being provided with three data disclosures related to the treatment decision, subjects were given a choice between surgery-now and watchful waiting. Data about surgical complications were presented in numerical format. The subjects were also asked whether they preferred communication with their physician about the chance (probability) of adverse outcomes-related to management strategies-in terms of words (such as possible or probable) or numbers (such as percentages). Of the 226 patients who chose either surgery-now or watchful waiting, 71.2% preferred risk information in terms of words only or numbers only: 44% words only, and 56% numbers only. Younger patients (OR = 1.06 per year; CI = 1.02-1.10, p = 0.0008) and those wanting risk communication in terms of words only (OR = 2.41; CI = 1.24-4.70, p = 0.01) tended to prefer surgery-now over watchful waiting as the management strategy for asymptomatic gland-confined prostate carcinoma. The authors conclude that there is a significant association between patients' preferences for risk communication with their physicians in terms of words only and a tendency to prefer early surgical intervention for prostate cancer when surgical risk data are provided numerically.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046280679

Download citation: RISBibTeXText

PMID: 10520677

DOI: 10.1177/0272989x9901900407


Related references

Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. Bju International 99(Suppl. 1): 13-6; Discussion 17-8, 2007

How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. Journal of the American Geriatrics Society 44(8): 934-937, 1996

Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). Journal of Urology 173(5): 1557-1561, 2005

Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy. Reviews in Urology 4(3): 141-146, 2002

Selecting treatment for high-risk, localized prostate cancer: the case for radical prostatectomy. Reviews in Urology 4(3): 147-152, 2002

First-line therapy for "high-risk prostate cancer". HELP - high intensity focused ultrasound (HIFU) and Eilgard in patients with high-risk prostate cancer - a prospective, randomized study (AP 62/10 of the AUO). Der Urologe. Ausg. a 53(7): 1063-1064, 2014

Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. BrachyTherapy 7(4): 277-9; Discussion 284-5, 2008

A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer. Annals of Surgical Oncology 21(12): 4026-4033, 2014

High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. International Journal of Radiation Oncology Biology Physics 82(4): 1376-1384, 2012

Treatment for high-risk localized prostate cancer. Nihon Rinsho. Japanese Journal of Clinical Medicine 72(12): 2212-2216, 2014

Role of novel risk classification method, Prostate Cancer Risk Index (PRIX) for clinically localized prostate cancer after high-dose-rate interstitial brachytherapy as monotherapy. Anticancer Research 34(6): 3077-3081, 2014

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer 120(11): 1620-1629, 2014

Using Robust Treatment Planning of Intensity Modulated Proton Therapy to Address Rectal Volume Uncertainty in High Risk Prostate Cancer Patients. International Journal of Radiation Oncology*Biology*Physics 102(3): e526-e527, 2018

High-risk localized prostate cancer: a case for early chemotherapy. Journal of Clinical Oncology 23(32): 8186-8191, 2005

Contemporary treatment of high-risk localized prostate cancer. Expert Review of Anticancer Therapy 10(7): 1069-1076, 2010